• 1
    Swisher SG, Hunt KK, Holmes EC, et al. Changes in the surgical management of esophageal cancer from 1970 to 1993. Am J Surg. 1995; 69: 609614.
  • 2
    Muller JM, Erasmi H, Stelzner M, et al. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990; 77: 845857.
  • 3
    Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002; 347: 16621669.
  • 4
    Roth JA, Pass HI, Flanagan MM, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg. 1988; 96: 242248.
  • 5
    Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001; 234: 520531.
  • 6
    Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002; 236: 376385.
  • 7
    Swisher SG, Holmes EC, Hunt KK, et al. The role of neoadjuvant therapy in surgically resectable esophageal cancer. Arch Surg. 1996; 131: 819825.
  • 8
    Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993; 11: 11181123.
  • 9
    Donington JS, Miller DL, Allen MS, et al. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg. 2003; 24: 631637.
  • 10
    Swisher SG, Ajani JA, Komaki R, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003; 57: 120127.
  • 11
    Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003; 21: 428432.
  • 12
    Brucher BLDM, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001; 233: 300309.
  • 13
    Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002; 13: 361368.
  • 14
    American Joint Commission on Cancer. Esophagus. In: GreeneFL, PageDL, FlemingID, FritzAG, BalchCM, HallerDG, et al., editors. American Joint Committee on Cancer cancer staging manual. 6th edition. New York: Springer-Verlag, 2002: 301346.
  • 15
    Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335: 462467.
  • 16
    Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001; 19: 305313.
  • 17
    Burmeister BH, Smithers BM, Fitzgerald L, et al. A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 130a.
  • 18
    Kelsen DP, Ginsberg R, Pajak TG, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998; 339: 19791984.
  • 19
    Mandard A-M, Dalibard F, Mandard J-C, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer. 1994; 73: 26802686.
  • 20
    Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993; 34: 419421.
  • 21
    Haberkorn U, Ziegler SI, Oberdorfer F, et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol. 1994; 21: 827834.
  • 22
    Nakamura R, Obara T, Katsuragawa S, et al. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med. 2002; 20: 181186.
  • 23
    Greven KM, Williams DW, McGuirt WF, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001; 23: 942946.
  • 24
    Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol. 2002; 31: 690694.
  • 25
    Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg. 2002; 73: 259264.
  • 26
    Rose DM, Delbeke D, Beauchamp RD, et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg. 1999; 229: 729737.
  • 27
    Bakheet SM, Saleem M, Powe J, Al-Amro A, Larsson SG, Mahassin Z. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med. 2000; 25: 273278.
  • 28
    Bhargava P, Reich P, Alavi A, et al. Radiation-induced esophagitis on FDG PET imaging. Clin Nucl Med. 2003; 28: 849850.
  • 29
    Gradinscak DJ, Fulham MJ, Mohamed A, et al. Skeletal muscle uptake detected on FDG PET 48 hours after exertion. Clin Nucl Med. 2003; 28: 840841.
  • 30
    Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19: 30583065.